Open AccessPB2106: REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT WHO RECEIVE HDMTX: PHASE 2
Author(s) -
De La Fuente A.,
Peñalver F. J.,
Herrera P.,
Cordoba R.,
Martinez Chamorro C.,
Olave M. T.,
Jarque I.,
Navarro M. B.,
Estévez M.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000851256.24064.82
Subject(s) - medicine , primary central nervous system lymphoma , adverse effect , mucositis , methotrexate , lymphoma , diffuse large b cell lymphoma , toxicity , oncology , surgery